In our project we aim to reassess the role of Lyn in glioma by benchmarking its function as a druggable therapeutic in three-dimensional disease models recapitulating the spectra of transcriptional subtypes of glioblastoma and different prominent brain cancer DNA mutation patterns [2]. The gene discussed is LYN; the disease is brain cancer.